



UPCOMING BIOALLIANCE PHARMA'S PRESENTATIONS AT INTERNATIONAL CONFERENCES ON INFECTIOUS DISEASES AND ONCOLOGY

Paris, May 19, 2009 – BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to therapies and supportive care for cancer and AIDS patients, today announced its scientific communications at upcoming international conferences on infectious diseases and oncology:

Loramyc[®], indicated for fungal infections in immune-compromised patients with HIV or cancer

The 2009 American Society of Clinical Oncology (ASCO) Annual Meeting

May 29 to June 2, 2009 - Orlando, Florida, USA.

Abstract: "*Prevalence and management of oropharyngeal candidiasis (OPC) by medical and radiation oncologists in cancer patients*".

At the American Conference for the Treatment of HIV (ACTHIV) that took place on May 15-17, 2009 in Denver, Colorado, USA, BioAlliance Pharma presented the poster: "Once-Daily Miconazole Mucoadhesive Buccal Tablet is an Effective and Safe Treatment for Oropharyngeal Candidiasis".

Amp[™], a biotherapy for Metastatic Melanoma treatment

American Society of Gene Therapy (ASGT) 12th Annual Meeting

May 27-30, 2009 - San Diego, California, USA

Poster: "*Complete Melanoma Regressions after Electrotransfer of the p-AMEP[™] Plasmid Coding for an Anti-Angiogenic and Anti-Metastatic Peptide*", May 28.

Anti-integrases: new antiretroviral drugs for the treatment of resistant HIV-1

XVIII International HIV Drug Resistance Workshop

June 9-13, 2009 - Fort Myers, Florida, USA

Oral communication and poster: "*New integrase binding inhibitors acting in synergy with Raltegravir*", June 12.

Irinotecan SRN oral formulation for the treatment of advanced colorectal cancer

2nd Pharmaceutical Sciences Fair and Exhibition (PharmSciFair)

June 8-12, 2009, Nice, France

Oral communication: "*Sustained Release Nanoparticles (SRN) for oral administration of Irinotecan*", June 10.

About BioAlliance Pharma

As a preferred partner for hospital-based specialists, BioAlliance Pharma is a company which develops and markets innovative products in France, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, our targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs.

For more information, visit the BioAlliance Pharma web site at <http://www.bioalliancepharma.com>.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document filed with the AMF on April 7, 2009, which is available on the AMF website (<http://www.amf-france.org>) or on BioAlliance Pharma S.A.'s website (<http://www.bioalliancepharma.com>).

BioAlliance Pharma SA

Dominique Costantini, President and CEO

Tel.: +33 1 45 58 76 01

dominique.costantini@bioalliancepharma.com

Nicolas Fellmann, CFO

Tel.: +33 1 45 58 71 00

nicolas.fellmann@bioalliancepharma.com

ALIZE RP

Caroline Carmagnol

Tel.: +33 6 64 18 99 59 / caroline@alizerp.com